Noile-Immune Biotech (TSE:4893) EV-to-FCF: (As of Jul. 11, 2026)


TSE:4893 Noile-Immune Biotech Inc TSE:4893
49 GF Score
Price 円136.00
GF Value 円4.34
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Noile-Immune Biotech's Enterprise Value is 円2,145.48 Mil. Noile-Immune Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.00 Mil. Therefore, Noile-Immune Biotech's EV-to-FCF for today is .

The historical rank and industry rank for Noile-Immune Biotech's EV-to-FCF or its related term are showing as below:

TSE:4893' s EV-to-FCF Range Over the Past 10 Years
Min: -2.45   Med: 0   Max: 0
Current: -2.45

TSE:4893's EV-to-FCF is ranked worse than
100% of 330 companies
in the Biotechnology industry
Industry Median: 16.36 vs TSE:4893: -2.45

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-11), Noile-Immune Biotech's stock price is 円136.00. Noile-Immune Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-7.500. Therefore, Noile-Immune Biotech's PE Ratio (TTM) for today is At Loss.


Noile-Immune Biotech  (TSE:4893) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Noile-Immune Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=136.00/-7.500
=At Loss

Noile-Immune Biotech's share price for today is 円136.00.
Noile-Immune Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-7.500.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Noile-Immune Biotech EV-to-FCF Related Terms


Noile-Immune Biotech EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech EV-to-FCF Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
Get a 7-Day Free Trial 0.00 0.00 -4.15 -3.03 -2.45

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.45 0.00

TSE:4893 vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, Noile-Immune Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noile-Immune Biotech EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Noile-Immune Biotech's EV-to-FCF falls into.


TSE:4893
49GF Score
Noile-Immune Biotech Inc TSE:4893
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech EV-to-FCF Calculation

Noile-Immune Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2145.478/0
=

Noile-Immune Biotech's current Enterprise Value is 円2,145.48 Mil.
Noile-Immune Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円136.00 is trading 3033.6% above its estimated GF Value™ of 円4.34. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • EV-to-FCF:
  • GF Value™: 円4.34 vs. price of 円136.00 (3033.6% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
49GF Score

Get the complete analysis for TSE:4893

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円136.00
Price
円4.34
GF Value